Abstract Details

Title Frontal Low Delta Spectral Power is Lower in Patients with Parkinson’s Disease than in Matched Controls

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 243

Objective Determine whether patients with Parkinson’s disease (PD) have reduced low delta spectral power (0.5-2 Hz) during non-rapid eye movement (non-REM) sleep stage 3 (N3) compared to matched non-PD controls.

Background

Slow-wave sleep (N3) plays an essential role in memory consolidation(1,2). Delta spectral power in N3 is vital for cognitive function in both healthy older adults and PD(3,4). Prior studies comparing delta spectral power in PD and non-PD controls have provided inconsistent findings (a common limitation of these studies was the small sample size)(5,6).

Design/Methods PD participants (N=56) and non-PD controls (N=28), matched for age, sex, and race, underwent polysomnography evaluation. We manually rejected movement and electrical artifacts in frontal leads (F3 and F4) and performed quantitative sleep EEG analyses during N3. Delta spectral power was calculated using a frequency range of 0.5-2 Hz, a frequency resolution of 1 Hz, and Welch’s method on 30-second sleep epochs during N3. We used the Wilcoxon/Kruskal-Wallis test to calculate the differences between the two groups.

Results Baseline demographics showed no group-level differences in age, sex, race, or amount of time spent in N3. Individual group level descriptive statistics showed 121.7 (98.2-205.3) microVolts²/Hz for median (IQR) frontal delta power during N3 in the PD group and 164.8 (131.7-256) microVolts²/Hz in the non-PD control group. Overall, the PD group showed a significantly reduced spectral power in the low delta frequency range (z=-2.37, p=0.0175) compared to the non-PD controls.

Conclusions

Individuals with PD have reduced low absolute delta power during N3 as compared to matched non-PD controls. Because patients with PD develop early cognitive impairment compared to non-PD controls(7), our findings are an essential step in identifying delta spectral power as a potential non-invasive marker to detect these changes. Future studies should evaluate other sleep quantitative EEG markers to identify mechanisms underlying sleep micro-architectural differences between PD and non-PD populations.

Authors/Disclosures
Adeel A. Memon, MD (West Virginia University) PRESENTER	The institution of Dr. Memon has received research support from NIH/NINDS.
Corina Catiul (UAB)	No disclosure on file
	No disclosure on file
	No disclosure on file
Allen Joop, MS (University of Alabama At Birmingham)	Mr. Joop has nothing to disclose.
Raima A. Memon, MBBS (University of Alabama At Birmingham)	Dr. Memon has nothing to disclose.
	No disclosure on file
Svjetlana Miocinovic, MD, PhD (Emory University)	Dr. Miocinovic has nothing to disclose.
Amy W. Amara, MD PhD (University of Colorado Anschutz Medical Center)	The institution of Dr. Amara has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Photopharmics, Inc. The institution of Dr. Amara has received research support from Michael J Fox Foundation for Parkinson's Research . The institution of Dr. Amara has received research support from Biogen Idec. The institution of Dr. Amara has received research support from NIH.

��ɫ��

��ɫ��